Oncogenic activation of PI3K/AKT signaling pathway, together with epigenetic aberrations are the characters of castration-resistant prostate cancer (CRPC). UHRF1 as a key epigenetic regulator, plays a critical role in prostate cancer (PCa) development, and its expression is positively correlated with the degree of malignancy. In this present study we investigated the potential regulatory mechanism of AKT1 on UHRF1, and further validated the in vitro and in vivo anticancer efficacy of AKT phosphorylation inhibitor MK2206 in combination with abiraterone. Both UHRF1 and p-AKT aberrantly overexpressed in the abiraterone-resistant PCa cells. Further studies revealed that AKT1 protein interacts with UHRF1, and AKT1 directly phosphorylates UHRF1 via the site Thr-210. MK2206 induced UHRF1 protein degradation by inhibiting AKT1-induced UHRF1 phosphorylation, and then reduced the interaction between UHRF1 and deubiquitinase USP7, while promoted the interaction between UHRF1 and E3 ubiquitin protein ligase BTRC. MK2206 significantly promoted the sensitivity of abiraterone-refractory PCa cells and xenografts to abiraterone by decreasing UHRF1 protein level, and reversed the phenotype of NEPC, evently induced cellular senescence and cell apoptosis. Altogether, our present study for the first time revealed a novel molecular mechanism of abiraterone resistance through PI3K/AKT-UHRF1 pathway, and provided a novel therapeutic modality by targeting PI3K/AKT1 to promote the drug sensitivity of abiraterone in PCa patients.
Oncogenic activation of PI3K/AKT signaling pathway, together with epigenetic aberrations is the characters of castration-resistant prostate cancer(CRPC). UHRF1 as a key epigenetic regulator, plays a critical role in prostate cancer (PCa) development, and its expression is closely associated with tumor malignancy. This present study investigated the potential regulatory relationship between AKT1 and UHRF1, and further validated the in vitro and in vivo anti-PCa efficacy of AKT phosphorylation inhibitor MK2206 in combination with abiraterone. Both UHRF1 and p-AKT aberrantly overexpressed in the abiraterone-resistant PCa cells. Further studies revealed that AKT1 protein interacts UHRF1, and AKT1 directly phosphorylates UHRF1 via the site Thr 210. MK2206 induced UHRF1 protein degradation by disrupting AKT1-induced UHRF1 phosphorylation, and then reduced the interaction between UHRF1 and deubiquitinating enzyme USP7, while promoted the interaction between UHRF and E3 ubiquitin protein ligase (BTRC). MK2206 significantly promoted the sensitivity of abiraterone-refractory PCa cells and xenografts to abiraterone by downregulating the levels of UHRF1, and reversed the transdifferentiation of NEPC (SYP and NCAM1), even activated cell senescence (p21 upregulation) and cell apoptosis (cleaved-PARP). Altogether, our present study for the first time revealed a novel molecular mechanism of abiraterone resistance through PI3/AKT-UHRF1 pathway, and provided a novel therapeutic modality by targeting PI3/AKT1 to promote the drug sensitivity of abiraterone in PCa patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.